The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Abstract
Commonly, the central objective of Phase II clinical trials is the assessment of the antitumor 'therapeutic efficacy' of a specific treatment regimen. It is of interest to formulate test procedures which can be employed in these trials to decide whether or not this therapeutic efficacy warrants further investigation. For ethical reasons, these procedures should allow for early termination if initial results are extreme. In this paper, a one-sample multiple testing procedure is proposed which employs the standard single-stage test procedure at the last test, and which both allows for early termination and essentially preserves the size, power and simplicity of the single-stage procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Repeated Significance Tests on Accumulating Data
Armitage, P., McPherson, C. K., & Rowe, B. C. (1969) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2343787 · Cited by 761
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Predictive Probability Early Termination Plans For Phase II Clinical Trials
Herson, J. (1979) · Biometrics · doi:10.2307/2530109 · Cited by 140
Multiple-Stage Procedures for Drug Screening
Schultz, J. R., Nichol, F. R., Elfring, G. L., & Weed, S. D. (1973) · Biometrics · doi:10.2307/2529393 · Cited by 89
Two-stage plans for patient accrual in phase II cancer clinical trials.
Lee, Y. J., Staquet, M. J., Simon, R. M., Catane, R., & Muggia, F. M. (1979) · PubMed · Cited by 47
Cited by
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
“Proving the null hypothesis” in clinical trials
Blackwelder, W. C. (1982) · Controlled Clinical Trials · doi:10.1016/0197-2456(82)90024-1 · Cited by 887
Rougier, P., Adenis, A., Ducreux, M., de Forni, M., Bonneterre, J., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00072-1 · Cited by 751
Lee, N., Harris, J., Garden, A. S., Straube, W., Glisson, B., Xia, P., Bosch, W., Morrison, W. H., Quivey, J., Thorstad, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9109 · Cited by 706
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., & Tarassoff, P. G. (1994) · Investigational New Drugs · doi:10.1007/bf00873232 · Cited by 435
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Videtic, G. M. M., Hu, C., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Schild, S. E., Komaki, R., Urbanic, J. J., & Choy, H. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2260 · Cited by 414
Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408
Sample size tables for exact single‐stage phase II designs
A'Hern, R. P. (2001) · Statistics in Medicine · doi:10.1002/sim.721 · Cited by 399
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Jaccard, A., Gachard, N., Marin, B., Rogez, S., Audrain, M., Suarez, F., Tilly, H., Morschhauser, F., Thieblemont, C., Ysebaert, L., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307454 · Cited by 381
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70303-5 · Cited by 359
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
Byrne, M. J., Davidson, J. A., Musk, A. W., Dewar, J., van Hazel, G., Buck, M., de Klerk, N. H., & Robinson, B. W. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.25 · Cited by 334
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., & Christian, M. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.265 · Cited by 331
Laurent, C., Kouanfack, C., Koulla-Shiro, S., Nkoué, N., Bourgeois, A., Calmy, A., Lactuock, B., Nzeusseu, V., Mougnutou, R., Peytavin, G., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16586-0 · Cited by 309
Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P. C., Howe, C. J., Doyle, T., Pointon, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 309
Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes
Thall, P. F., Simon, R. M., & Estey, E. H. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140404 · Cited by 299
Grill, J., Sainte-Rose, C., Jouvet, A., Gentet, J.-C., Lejars, O., Frappaz, D., Doz, F., Rialland, X., Pichon, F., Bertozzi, A.-I., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70252-7 · Cited by 280
Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4207 · Cited by 280
Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.057 · Cited by 277
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 277
Quoix, E., Ramlau, R., Westeel, V., Papai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J.-L., Stoelben, E., Braun, D., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70259-5 · Cited by 269
Lubner, S. J., Mahoney, M. R., Kolesar, J. L., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W.-P., Horvath, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg371 · Cited by 261
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
Muro, K., Hamaguchi, T., Ohtsu, A., Boku, N., Chin, K., Hyodo, I., Fujita, H., Takiyama, W., & Ohtsu, T. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh231 · Cited by 257
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall, P. F., Simon, R. M., & Estey, E. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.296 · Cited by 131
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen, C. I., Bergsagel, P. L., Paul, H., Xu, W., Lau, A., Dave, N., Kukreti, V., Wei, E., Leung-Hagesteijn, C., Li, Z. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8133 · Cited by 115
Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawa, K., Tsushita, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh176 · Cited by 108
Besch, G., Perrotti, A., Mauny, F., Puyraveau, M., Baltres, M., Flicoteaux, G., Salomon du Mont, L., Barrucand, B., Samain, E., Chocron, S., et al. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001838 · Cited by 38
A Bayesian Approach to the Correction for Multiplicity
de Jong, T. (2019) · doi:10.31234/osf.io/s56mk · Cited by 35
Grossi, F., Jaśkiewicz, P., Ferreira, M., Czyżewicz, G., Kowalski, D., Ciuffreda, L., Garcia-Gomez, R., Caruso, S., Bosch-Barrera, J., Gautier, S., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211022905 · Cited by 5
Metadata
- Authors
- Fleming, T. R.
- Venue
- Biometrics
- Publisher
- JSTOR
- Published
- 1982-03
- Volume
- 38
- Issue
- 1
- Pages
- 143
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W1984254136
- Cited by
- 1,003
- References
- 7
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.